Peter Lockwood

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint The Pharmacokinetics of Pregabalin in Breast Milk, Plasma, and Urine of Healthy Postpartum Women
    Peter A Lockwood
    Pfizer Inc, Global Innovative Pharma Business, Clinical Pharmacology, Groton, CT, USA
    J Hum Lact . 2016
  2. ncbi request reprint The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain
    Peter A Lockwood
    Clinical Pharmacokinetics and Pharmacodynamics, Pfizer Global Research and Development, Ann Arbor, MI, USA
    Pharm Res 20:1752-9. 2003
  3. ncbi request reprint Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease
    Peter Lockwood
    Pfizer Global Research and Development, Ann Arbor, Michigan, USA
    Pharm Res 23:2050-9. 2006
  4. ncbi request reprint How modeling and simulation have enhanced decision making in new drug development
    Raymond Miller
    Pfizer Global Research and Development, Pfizer Inc, Ann Arbor, MI 48105, USA
    J Pharmacokinet Pharmacodyn 32:185-97. 2005
  5. doi request reprint Quantitative prediction of renal transporter-mediated clinical drug-drug interactions
    Bo Feng
    Department of Pharmacokinetics and Drug Metabolism, Pfizer Global Research and Development, Groton, Connecticut 06340, United States
    Mol Pharm 10:4207-15. 2013

Collaborators

Detail Information

Publications5

  1. ncbi request reprint The Pharmacokinetics of Pregabalin in Breast Milk, Plasma, and Urine of Healthy Postpartum Women
    Peter A Lockwood
    Pfizer Inc, Global Innovative Pharma Business, Clinical Pharmacology, Groton, CT, USA
    J Hum Lact . 2016
    ..Limited data exist on the presence of pregabalin in human breast milk of nursing mothers...
  2. ncbi request reprint The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain
    Peter A Lockwood
    Clinical Pharmacokinetics and Pharmacodynamics, Pfizer Global Research and Development, Ann Arbor, MI, USA
    Pharm Res 20:1752-9. 2003
    ..The likelihood of demonstrating at least a one-point change for each available dose strength was also calculated...
  3. ncbi request reprint Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease
    Peter Lockwood
    Pfizer Global Research and Development, Ann Arbor, Michigan, USA
    Pharm Res 23:2050-9. 2006
    ..e., Ho: Drug Effect = 0). We evaluated if a crossover design would allow smaller and shorter duration trials...
  4. ncbi request reprint How modeling and simulation have enhanced decision making in new drug development
    Raymond Miller
    Pfizer Global Research and Development, Pfizer Inc, Ann Arbor, MI 48105, USA
    J Pharmacokinet Pharmacodyn 32:185-97. 2005
    ....
  5. doi request reprint Quantitative prediction of renal transporter-mediated clinical drug-drug interactions
    Bo Feng
    Department of Pharmacokinetics and Drug Metabolism, Pfizer Global Research and Development, Groton, Connecticut 06340, United States
    Mol Pharm 10:4207-15. 2013
    ..The models were further used to evaluate the renal DDIs of Pfizer clinical candidates/drugs, and the overall predictability demonstrates their utility in the drug discovery and development settings. ..